- Home
- THAR vs BJDX Comparison
THAR vs BJDX Comparison
Compare THAR & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- BJDX
- Stock Information
- Founded
- THAR 2017
- BJDX 2015
- Country
- THAR United States
- BJDX United States
- Employees
- THAR N/A
- BJDX N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- THAR Health Care
- BJDX Health Care
- Exchange
- THAR Nasdaq
- BJDX Nasdaq
- Market Cap
- THAR 3.3M
- BJDX 2.9M
- IPO Year
- THAR 2022
- BJDX 2021
- Fundamental
- Price
- THAR $1.51
- BJDX $2.25
- Analyst Decision
- THAR Strong Buy
- BJDX
- Analyst Count
- THAR 1
- BJDX 0
- Target Price
- THAR $17.00
- BJDX N/A
- AVG Volume (30 Days)
- THAR 26.3K
- BJDX 2.0M
- Earning Date
- THAR 05-12-2025
- BJDX 05-13-2025
- Dividend Yield
- THAR N/A
- BJDX N/A
- EPS Growth
- THAR N/A
- BJDX N/A
- EPS
- THAR N/A
- BJDX N/A
- Revenue
- THAR N/A
- BJDX N/A
- Revenue This Year
- THAR N/A
- BJDX N/A
- Revenue Next Year
- THAR N/A
- BJDX $55.56
- P/E Ratio
- THAR N/A
- BJDX N/A
- Revenue Growth
- THAR N/A
- BJDX N/A
- 52 Week Low
- THAR $0.95
- BJDX $1.46
- 52 Week High
- THAR $6.39
- BJDX $236.00
- Technical
- Relative Strength Index (RSI)
- THAR 54.61
- BJDX 58.09
- Support Level
- THAR $1.41
- BJDX $1.49
- Resistance Level
- THAR $1.64
- BJDX $1.82
- Average True Range (ATR)
- THAR 0.11
- BJDX 0.18
- MACD
- THAR 0.01
- BJDX 0.07
- Stochastic Oscillator
- THAR 63.86
- BJDX 79.17
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.